Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/23/2025

Erectile Dysfunction Treatment

First-Line Treatment: PDE5 Inhibitors

  • The American Urological Association recommends oral PDE5 inhibitors, such as sildenafil, tadalafil, or vardenafil, as the first-line treatment for erectile dysfunction, with tadalafil offering the additional advantage of potentially improving residual urinary symptoms 1, 2
  • PDE5 inhibitors are safe and effective in patients who are 18 months post-TURP with well-controlled blood pressure, according to the American Urological Association 1
  • Vardenafil or sildenafil are equally effective alternatives to tadalafil if it is not suitable, as suggested by the American Urological Association 1

Second-Line Treatment: Intraurethral Alprostadil

  • If PDE5 inhibitors fail or are contraindicated, intraurethral alprostadil suppositories are the next option, though they are less effective than oral medications, as stated by the American Urological Association 1
  • The first dose of intraurethral alprostadil must be administered under healthcare provider supervision due to a 3% risk of syncope/hypotension, according to the American Urological Association 1
  • Combination therapy with alprostadil plus a penile constriction device or PDE5 inhibitor shows increased efficacy over alprostadil alone, as suggested by the American Urological Association 1

Third-Line Treatment: Intracavernous Injection Therapy

  • Intracavernous injection therapy is the most effective non-surgical treatment for ED, but is invasive and carries the highest risk of priapism, as stated by the American Urological Association 1
  • The initial dose of intracavernous injection therapy must be administered under healthcare provider supervision to determine effective dosing and monitor for prolonged erection, according to the American Urological Association 1
  • Alprostadil (PGE1) monotherapy is most commonly used, though combination therapy (bimix/trimix with papaverine and phentolamine) can increase efficacy or reduce side effects, as suggested by the American Urological Association 1

Important Post-TURP Context

  • The TURP procedure has a 10-13% risk of causing erectile dysfunction, which is relevant to understanding the etiology of current symptoms, as stated by the American Urological Association 3
  • Erectile dysfunction is not due to ongoing prostatic obstruction, so alpha-blockers or 5-alpha-reductase inhibitors have no role in treatment, according to the European Association of Urology 5

Clinical Pitfalls to Avoid

  • Do not assume one failed PDE5 inhibitor means all will fail - while data is limited, trying a different PDE5 inhibitor is reasonable before moving to more invasive options, as suggested by the American Urological Association 1